Sanofi has been granted a patent for a drug injection device that includes a cartridge for holding a drug, processors that control the device’s operation, a member with conductive surfaces connected to the processors, and a drive mechanism that activates the processors when it makes electrical contact with the conductive surfaces. The drive mechanism also physically displaces the member. GlobalData’s report on Sanofi gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sanofi, NSAID cancer drugs was a key innovation area identified from patents. Sanofi's grant share as of September 2023 was 60%. Grant share is based on the ratio of number of grants to total number of patents.
Drug injection device with enabled and sleep states
A recently granted patent (Publication Number: US11771832B2) describes a drug injection device with unique features. The device includes a cartridge for holding a drug and one or more processors that can operate in an enabled state and a sleep state. These processors control the operation of the device and are electrically connected to a member in the cartridge, which has two conductive surfaces. The device also includes a drive mechanism with a conductive element that can make electrical contact with the conductive surfaces of the member. When the conductive element makes contact with the conductive surfaces, the processors transition from the sleep state to the enabled state, and the drive mechanism physically displaces the member.
In one embodiment, the member is a stopper, and the conductive element is located on the bottom surface of a plunger in the drive mechanism. The conductive element moves towards the member and makes electrical contact with the conductive surfaces when the drive mechanism is engaged. This engagement typically occurs during the priming of the drug injection device.
When the conductive element makes electrical contact with the conductive surfaces, it activates a reset circuit in the processors. The device also includes one or more non-transitory computer-readable media that store instructions for the processors to control the operation of the drug injection device. These media may include a ferroelectric random access memory (FRAM) that can store data without a continuous supply of power.
Overall, this patent describes a drug injection device with a unique mechanism for controlling its operation. The inclusion of processors, conductive surfaces, and a drive mechanism allows for precise control and activation of the device. The use of non-transitory computer-readable media, such as FRAM, ensures data storage even without a continuous power supply. This innovation could potentially improve the functionality and reliability of drug injection devices in the future.
To know more about GlobalData’s detailed insights on Sanofi, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
